The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | B | Blood and blood forming organs | |
| 2 | B02 | Antihemorrhagics | |
| 3 | B02B | Vitamin K and other hemostatics | |
| 4 | B02BX | Other systemic hemostatics | |
| 5 | B02BX06 |
| Active Ingredient | Description | |
|---|---|---|
| Emicizumab |
Emicizumab is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure. Emicizumab bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective haemostasis. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| HEMLIBRA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
